Truist Financial Corp Trims Stock Holdings in Eli Lilly and Company $LLY

Truist Financial Corp decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 5.2% in the 3rd quarter, Holdings Channel reports. The firm owned 357,383 shares of the company’s stock after selling 19,695 shares during the period. Truist Financial Corp’s holdings in Eli Lilly and Company were worth $272,682,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Eli Lilly and Company by 1.5% during the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after buying an additional 1,183,038 shares during the last quarter. Laurel Wealth Advisors LLC lifted its position in Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after acquiring an additional 11,537,661 shares during the period. Norges Bank purchased a new position in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $8,827,714,000. Jennison Associates LLC increased its holdings in shares of Eli Lilly and Company by 4.3% in the second quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock valued at $4,246,596,000 after purchasing an additional 226,620 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Eli Lilly and Company by 2.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock worth $4,178,010,000 after purchasing an additional 103,119 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 2.3%

LLY stock opened at $1,038.23 on Wednesday. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The firm has a market capitalization of $981.52 billion, a PE ratio of 50.79, a P/E/G ratio of 0.80 and a beta of 0.35. The company’s 50 day simple moving average is $1,058.15 and its 200-day simple moving average is $885.09.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.Eli Lilly and Company’s quarterly revenue was up 53.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a $1.73 dividend. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s payout ratio is currently 29.35%.

Analysts Set New Price Targets

LLY has been the topic of a number of analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eli Lilly and Company in a research report on Monday, December 1st. The Goldman Sachs Group raised their target price on shares of Eli Lilly and Company from $951.00 to $1,145.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Truist Financial boosted their price target on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a research note on Wednesday, November 19th. Morgan Stanley raised their price objective on shares of Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an “overweight” rating in a research report on Monday, November 24th. Finally, Scotiabank assumed coverage on Eli Lilly and Company in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 target price on the stock. Four research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $1,173.91.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to a development and commercialization deal worth up to $1.12 billion with Germany’s Seamless Therapeutics to target hearing‑loss treatments using Seamless’s gene‑editing platform — a sizable near‑term R&D/clinical collaboration that expands Lilly’s pipeline and long‑term growth optionality. Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless
• Positive Sentiment: Analyst and trade commentary highlights Lilly’s expanding oncology and AI investments (including a high‑profile Nvidia collaboration reported previously), which support expectations for continued top‑line and pipeline growth beyond GLP‑1 drugs. Eli Lilly (LLY) Oncology Pipeline and $1B Nvidia (NVDA) AI Partnership Signal Strong 2026 Growth
• Neutral Sentiment: Lilly reports expected earnings activity this week and investor pieces debate valuation after strong recent gains — earnings and guidance will be a near‑term catalyst but market reaction depends on execution vs. lofty expectations. Eli Lilly and Company (LLY) Expected to Announce Earnings on Wednesday
• Neutral Sentiment: Lilly completed a Phase 1/2 readout update for pirtobrutinib, moving that BTK inhibitor program forward — clinical progress supports pipeline value but will require further data to shift commercial outlook materially. Eli Lilly’s Pirtobrutinib Trial Completion Signals Next Phase in the BTK Inhibitor Race
• Negative Sentiment: The U.S. Medicare Drug Price Negotiation Program has named Lilly products for its next negotiation round, increasing the risk of mandated price reductions for covered medicines and potential margin pressure. US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
• Negative Sentiment: Data show Novo Nordisk more than doubled U.S. advertising spend behind Wegovy and Ozempic vs. Lilly’s GLP‑1 ads in 1H–3Q25, signaling aggressive marketing that could weigh on Lilly’s market share and growth assumptions for weight‑loss products. Exclusive: Novo’s Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows
• Negative Sentiment: Hospital groups are urging regulators to block a new Lilly 340B claims‑data submission policy, creating regulatory friction and possible reputational/headwind risks with payers and providers. AHA Urges HRSA to Stop Eli Lilly’s New Policy on 340B Hospitals From Going into Effect

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.